Stifel stays Buy rated on X4 Pharmaceuticals (XFOR) as mavorixafor ph3 trial remains on-track
Tweet Send to a Friend
Stifel analyst James Condulis reiterated a Buy rating and $10.00 price target on X4 Pharmaceuticals (NASDAQ: XFOR)The analyst commented, "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
